Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer

详细信息    查看全文

• 作者：Yong Liu (1)
  Jingyu Deng (1)
  Xuegang Luo (2)
  Yuan Pan (1)
  Li Zhang (1)
  Rupeng Zhang (1)
  Han Liang (1)
  
• 关键词：Gastric cancer ; SMYD3 ; STAT3 ; pSTAT3 ; Prognosis
• 刊名：Medical Oncology
• 出版年：2015
• 出版时间：January 2015
• 年：2015
• 卷：32
• 期：1
• 全文大小：1,592 KB
• 参考文献：1. Yuan Y. A survey and evaluation of population-based screening for gastric cancer. Cancer Biol Med. 2013;10:72-0.
  2. Lin Y, Ueda J, Kikuchi S, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011;17:4421-. CrossRef
  3. Abe N, Watanabe T, Suzuki K, et al. Risk factors predictive of lymph node metastasis in depressed early gastric cancer. Am J Surg. 2002;183:168-2. CrossRef
  4. Hamamoto R, Furukawa Y, Morita M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004;6:731-0. CrossRef
  5. Kim H, Heo K, Kim JH, et al. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. J Biol Chem. 2009;284:19867-7. CrossRef
  6. Chen LB, Xu JY, Yang Z, et al. Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration. World J Gastroenterol. 2007;13:5718-4. CrossRef
  7. He C, Xu J, Zhang J, et al. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol. 2012;43:1425-5. CrossRef
  8. Luo XG, Xi T, Guo S, et al. Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells. IUBMB Life. 2009;61:679-4. CrossRef
  9. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798-09. CrossRef
  10. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8:945-4.
  11. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000;19:6613-6. CrossRef
  12. Deng JY, Sun D, Liu XY, et al. STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroentrol. 2010;16:5380-. CrossRef
  13. Kim DY, Cha ST, Ahn DH, et al. STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol. 2009;24:646-1. CrossRef
  14. Dolled-Filhart M, Camp RL, Kowalski DP, et al. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat 3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res. 2003;9:594-00.
  15. Deng J, Liang H, Ying G, et al. Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer. Oncotarget. 2014;5:3173-3.
  16. Hamamoto R, Silva FP, Tsuge M, et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006;97:113-. CrossRef
  17. Wang SZ, Luo XG, Shen J, et al. Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cells growth and invasion in vitro. BMB Rep. 2008;41:294-. CrossRef
  18. Groner B. Determinants of the extent and duration of STAT3 signaling. Jak-Stat. 2012;1:211-. CrossRef
  19. Shah NG, Trivedi TI, Tankshali RA, et al. Stat3 expression in oral squamous cell carcinoma: association with clinicopathological parameters and survival. Int J Biol Mark. 2006;21:175-3.
  20. Gong W, Wang L, Yao JC, et al. Expression of activat
• 作者单位：Yong Liu (1)
  Jingyu Deng (1)
  Xuegang Luo (2)
  Yuan Pan (1)
  Li Zhang (1)
  Rupeng Zhang (1)
  Han Liang (1)
  
  1. Department of Gastric Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China
  2. Key Laboratory of Industrial Microbiology, Ministry of Education, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, 300457, China
  
• ISSN：1559-131X

文摘

This study aimed to investigate mRNA and protein expressions of SET and MYND domain-containing protein 3 (SMYD3), STAT3, and phosphorylated STAT3 (pSTAT3) in gastric cancer (GC). This study was also conducted to explore the correlations between these proteins and biological behaviors of GC. SMYD3, STAT3, and pSTAT3 expressions were detected in GC tissues and adjacent non-tumor tissues by semiquantitative/quantitative reverse transcription polymerase chain reaction and Western blot analysis. SMYD3, STAT3, and pSTAT3 expressions in tissue sections were evaluated by immunohistochemistry. Staining results were compared with clinicopathological characteristics and the outcome of patients. The mRNA expression levels of SMYD3 or STAT3 and the protein expression levels of SMYD3, STAT3, or pSTAT3 in GC tissues were significantly higher than those in adjacent non-tumor tissues. Lymph node metastasis was identified as an independently relative factor for SMYD3 expression; the degree of differentiation and serosal invasion were identified as the independently relative factors for pSTAT3 expression in GC tissues. SMYD3 expression and STAT3 or pSTAT3 expressions in GC tissues were significantly and positively correlated. Multivariate analysis results demonstrated that primary tumor location, lymph node metastasis, SMYD3 expression, and pSTAT3 expression were independent prognostic indicators of GC. pSTAT3 expression was an optimal prognostic predictor of patients, as identified by Cox regression with Akaike’s information criterion value calculation. High SMYD3 and pSTAT3 expressions may indicate poor prognosis of patients with GC.